Literature DB >> 24711773

Immunoglobulin g4-associated cholangitis: the next great masquerader.

Andrew S Delemos1, Daniel S Pratt2.   

Abstract

Entities:  

Year:  2013        PMID： 24711773      PMCID： PMC3977647     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  14 in total

Review 1.  A clinical overview of IgG4-related systemic disease.

Authors:  Arezou Khosroshahi; John H Stone
Journal:  Curr Opin Rheumatol       Date:  2011-01       Impact factor: 5.006

2.  Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders.

Authors:  Y Masaki; L Dong; N Kurose; K Kitagawa; Y Morikawa; M Yamamoto; H Takahashi; Y Shinomura; K Imai; T Saeki; A Azumi; S Nakada; E Sugiyama; S Matsui; T Origuchi; S Nishiyama; I Nishimori; T Nojima; K Yamada; M Kawano; Y Zen; M Kaneko; K Miyazaki; K Tsubota; K Eguchi; K Tomoda; T Sawaki; T Kawanami; M Tanaka; T Fukushima; S Sugai; H Umehara
Journal:  Ann Rheum Dis       Date:  2008-08-13       Impact factor: 19.103

Review 3.  Immunoglobulin G4-associated cholangitis.

Authors:  Einar Björnsson
Journal:  Curr Opin Gastroenterol       Date:  2008-05       Impact factor: 3.287

4.  Utility of serum immunoglobulin G4 in distinguishing immunoglobulin G4-associated cholangitis from cholangiocarcinoma.

Authors:  Abdul M Oseini; Roongruedee Chaiteerakij; Abdirashid M Shire; Amaar Ghazale; Joseph Kaiya; Catherine D Moser; Ileana Aderca; Teresa A Mettler; Terry M Therneau; Lizhi Zhang; Naoki Takahashi; Suresh T Chari; Lewis R Roberts
Journal:  Hepatology       Date:  2011-08-08       Impact factor: 17.425

5.  Endoscopic retrograde cholangiography does not reliably distinguish IgG4-associated cholangitis from primary sclerosing cholangitis or cholangiocarcinoma.

Authors:  Evangelos Kalaitzakis; Michael Levy; Terumi Kamisawa; Gavin J Johnson; Todd H Baron; Mark D Topazian; Naoki Takahashi; Atsushi Kanno; Kazuichi Okazaki; Naoto Egawa; Kazushige Uchida; Kashif Sheikh; Zahir Amin; Tooru Shimosegawa; Neomal S Sandanayake; Nicholas I Church; Michael H Chapman; Stephen P Pereira; Suresh Chari; George J M Webster
Journal:  Clin Gastroenterol Hepatol       Date:  2011-06-06       Impact factor: 11.382

6.  Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis.

Authors:  Sanjay Y Bangarulingam; Einar Bjornsson; Felicity Enders; Emily G Barr Fritcher; Gregory Gores; Kevin C Halling; Keith D Lindor
Journal:  Hepatology       Date:  2010-01       Impact factor: 17.425

7.  Clinicopathological differentiation between sclerosing cholangitis with autoimmune pancreatitis and primary sclerosing cholangitis.

Authors:  Takayoshi Nishino; Hiroyasu Oyama; Etsuko Hashimoto; Fumitake Toki; Itaru Oi; Makio Kobayashi; Keiko Shiratori
Journal:  J Gastroenterol       Date:  2007-07-25       Impact factor: 7.527

8.  Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy.

Authors:  Amaar Ghazale; Suresh T Chari; Lizhi Zhang; Thomas C Smyrk; Naoki Takahashi; Michael J Levy; Mark D Topazian; Jonathan E Clain; Randall K Pearson; Bret T Petersen; Santhi Swaroop Vege; Keith Lindor; Michael B Farnell
Journal:  Gastroenterology       Date:  2007-12-07       Impact factor: 22.682

Review 9.  Diagnosis of autoimmune pancreatitis using its five cardinal features: introducing the Mayo Clinic's HISORt criteria.

Authors:  Suresh T Chari
Journal:  J Gastroenterol       Date:  2007-05       Impact factor: 7.527

10.  Rituximab therapy for refractory biliary strictures in immunoglobulin G4-associated cholangitis.

Authors:  Mark Topazian; Thomas E Witzig; Thomas C Smyrk; Jose S Pulido; Michael J Levy; Patrick S Kamath; Suresh T Chari
Journal:  Clin Gastroenterol Hepatol       Date:  2008-03       Impact factor: 11.382
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.